Cardiol Therapeutics (NASDAQ:CRDL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Cardiol Therapeutics (NASDAQ:CRDL) from a sell rating to a hold rating in a research report report published on Sunday.

Several other equities analysts have also commented on the stock. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Cardiol Therapeutics in a research report on Tuesday, February 10th. upgraded shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.50.

Cardiol Therapeutics Stock Up 0.7%

Shares of NASDAQ:CRDL opened at $1.40 on Friday. The stock has a market capitalization of $156.55 million, a price-to-earnings ratio of -5.00 and a beta of 0.82. Cardiol Therapeutics has a 1-year low of $0.80 and a 1-year high of $1.59. The company’s fifty day moving average is $1.07 and its two-hundred day moving average is $1.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.89 and a current ratio of 3.89.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its earnings results on Monday, March 30th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. Equities analysts anticipate that Cardiol Therapeutics will post -0.33 EPS for the current year.

Hedge Funds Weigh In On Cardiol Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Security National Bank of Sioux City Iowa IA acquired a new stake in Cardiol Therapeutics in the 4th quarter valued at about $31,000. Simplex Trading LLC lifted its holdings in Cardiol Therapeutics by 96.9% in the 4th quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock valued at $31,000 after acquiring an additional 15,842 shares during the last quarter. Boyer Financial Services Inc. acquired a new stake in Cardiol Therapeutics in the 4th quarter valued at about $33,000. Bank of America Corp DE lifted its holdings in Cardiol Therapeutics by 136.2% in the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock valued at $36,000 after acquiring an additional 15,255 shares during the last quarter. Finally, Susquehanna International Group LLP lifted its holdings in Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock valued at $100,000 after acquiring an additional 73,375 shares during the last quarter. Institutional investors own 12.49% of the company’s stock.

Key Cardiol Therapeutics News

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and a $9.00 target, and materially tightened/raised its model — boosting FY2026 EPS from ($0.41) to ($0.27) and improving FY2027 to ($0.34) (from ($0.51)). The firm also laid out -$0.06 quarterly EPS assumptions across 2026, signaling a more constructive outlook. HC Wainwright estimates
• Positive Sentiment: Canaccord Genuity reaffirmed its “Buy” rating with an $8.00 price target, a substantially higher objective than current levels — reinforcing bullish sentiment among institutional brokers. Benzinga article
• Neutral Sentiment: HC Wainwright’s published quarter-by-quarter EPS assumptions (Q1–Q4 2026 at ~$0.06 loss per share) provide a consistent near-term earnings path but do not introduce new catalysts beyond the improved FY guidance. HC Wainwright quarterly estimates
• Negative Sentiment: Brookline Capital trimmed several near-term estimates: Q3 2026 EPS lowered to ($0.08) from ($0.07), Q4 to ($0.09) and FY2026 to ($0.31) (from $0.29 prior). These downgrades introduce some caution about near-term results and pressure investor expectations. Brookline estimate changes

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.